Minerva Neurosciences (NERV) Stock Forecast, Price Target & Predictions
NERV Stock Forecast
Minerva Neurosciences stock forecast is as follows: an average price target of $5.00 (represents a 138.10% upside from NERV’s last price of $2.10) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.
NERV Price Target
The average price target for Minerva Neurosciences (NERV) is $5.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 138.10% upside from NERV's last price of $2.10.
NERV Analyst Ratings
According to 1 Wall Street analysts, Minerva Neurosciences's rating consensus is 'Hold'. The analyst rating breakdown for NERV stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Minerva Neurosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Douglas Tsao | H.C. Wainwright | $5.00 | $2.94 | 70.07% | 138.10% |
| May 02, 2024 | Douglas Tsao | H.C. Wainwright | $7.00 | $2.40 | 191.67% | 233.33% |
The latest Minerva Neurosciences stock forecast, released on Aug 07, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $5.00, which represents a 70.07% increase from the stock price at the time of the forecast ($2.94), and a 138.10% increase from NERV last price ($2.10).
Minerva Neurosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $6.00 |
| Last Closing Price | $2.10 | $2.10 | $2.10 |
| Upside/Downside | -100.00% | -100.00% | 185.71% |
In the current month, the average price target of Minerva Neurosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Minerva Neurosciences's last price of $2.10. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| May 02, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
Minerva Neurosciences's last stock rating was published by H.C. Wainwright on Aug 07, 2024. The company gave NERV a "Neutral" rating, the same as its previous rate.
Minerva Neurosciences Financial Forecast
Minerva Neurosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $20.00M | - | - | $333.33K | $333.33K | $574.00K | $24.00M |
| High Forecast | - | - | - | - | $20.00M | - | - | $333.33K | $333.33K | $574.00K | $24.00M |
| Low Forecast | - | - | - | - | $20.00M | - | - | $333.33K | $333.33K | $574.00K | $24.00M |
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Minerva Neurosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NERV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Minerva Neurosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-21.38M | $-7.50M | $-8.93M | $-7.47M |
| Avg Forecast | - | - | - | - | $16.19M | - | - | $269.79K | $269.79K | $464.58K | $-17.71M |
| High Forecast | - | - | - | - | $16.19M | - | - | $269.79K | $269.79K | $464.58K | $-14.17M |
| Low Forecast | - | - | - | - | $16.19M | - | - | $269.79K | $269.79K | $464.58K | $-21.25M |
| Surprise % | - | - | - | - | - | - | - | -79.24% | -27.81% | -19.23% | 0.42% |
undefined analysts predict NERV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Minerva Neurosciences's previous annual EBITDA (undefined) of $NaN.
Minerva Neurosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-21.31M | $-9.21M | $-10.59M | $-8.80M |
| Avg Forecast | $-2.72M | $-2.65M | $-6.81M | $-8.10M | $-7.95M | $-7.64M | $-7.34M | $-11.29M | $-13.15M | $-10.54M | $-20.89M |
| High Forecast | $-2.72M | $-2.65M | $-6.81M | $-8.10M | $-7.95M | $-7.64M | $-7.34M | $-11.29M | $-13.15M | $-10.54M | $-16.71M |
| Low Forecast | $-2.72M | $-2.65M | $-6.81M | $-8.10M | $-7.95M | $-7.64M | $-7.34M | $-11.29M | $-13.15M | $-10.54M | $-25.07M |
| Surprise % | - | - | - | - | - | - | - | 1.89% | 0.70% | 1.01% | 0.42% |
Minerva Neurosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NERV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Minerva Neurosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $2.63M | $3.00M | $3.44M | $4.25M |
| Avg Forecast | - | - | - | - | $17.68M | - | - | $294.66K | $294.66K | $507.40K | $10.08M |
| High Forecast | - | - | - | - | $17.68M | - | - | $294.66K | $294.66K | $507.40K | $12.10M |
| Low Forecast | - | - | - | - | $17.68M | - | - | $294.66K | $294.66K | $507.40K | $8.07M |
| Surprise % | - | - | - | - | - | - | - | 8.93% | 10.20% | 6.78% | 0.42% |
Minerva Neurosciences's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to NERV last annual SG&A of $2.63M (Dec 21).
Minerva Neurosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-3.99 | $-1.72 | $-1.98 | $-1.65 |
| Avg Forecast | $-0.36 | $-0.35 | $-0.90 | $-1.07 | $-1.05 | $-1.01 | $-0.97 | $-1.49 | $-1.74 | $-1.39 | $2.66 |
| High Forecast | $-0.36 | $-0.35 | $-0.90 | $-1.07 | $-1.05 | $-1.01 | $-0.97 | $-1.49 | $-1.74 | $-1.39 | $2.66 |
| Low Forecast | $-0.36 | $-0.35 | $-0.90 | $-1.07 | $-1.05 | $-1.01 | $-0.97 | $-1.49 | $-1.74 | $-1.39 | $2.66 |
| Surprise % | - | - | - | - | - | - | - | 2.68% | 0.99% | 1.42% | -0.62% |
According to undefined Wall Street analysts, Minerva Neurosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NERV previous annual EPS of $NaN (undefined).
Minerva Neurosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VIRX | Viracta Therapeutics | $0.15 | $8.00 | 5233.33% | Buy |
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| ALXO | ALX Oncology | $1.23 | $24.50 | 1891.87% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| CABA | Cabaletta Bio | $2.54 | $16.33 | 542.91% | Buy |
| KOD | Kodiak Sciences | $5.64 | $31.60 | 460.28% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| BMEA | Biomea Fusion | $6.42 | $22.75 | 254.36% | Buy |
| ZURA | Zura Bio | $3.15 | $10.00 | 217.46% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.39 | $7.00 | 192.89% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| EYPT | EyePoint Pharmaceuticals | $9.21 | $26.00 | 182.30% | Buy |
| ANNX | Annexon | $5.46 | $14.00 | 156.41% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| NERV | Minerva Neurosciences | $2.10 | $5.00 | 138.10% | Hold |
| LPTX | Leap Therapeutics | $2.70 | $5.50 | 103.70% | Buy |
| MREO | Mereo BioPharma Group | $3.49 | $6.75 | 93.41% | Buy |
| WVE | Wave Life Sciences | $14.21 | $22.14 | 55.81% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |